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INTRODUCTION 
Recently, many investigations about the mod-
ification of bone grafts with biological molecules and 
drugs have been performed broadly. These modified 
bone grafts enable a direct and a well-defined appli-
cation of drugs to infected or fractured hard tis-
sue
1,2)
. Bone grafts with biological substances or 
drugs are more efficient than systemic administration 
due to lower doses and reducing side effects
3)
. 
Besides, these modified bone grafts can determine 
suitable contents of drug for patients who demand 
actual contents for their disease. There are lots of 
bone grafts based on various materials. For bone 
grafts based on polymeric materials, their mechan-
ical and chemical properties are not good as ceramic 
materials. But most of ceramic bone grafts have 




However, some ceramic bone grafts have an ad-
vantage which does not need to sinter at high 
temperature. As the representable ones, those are 
materials based on calcium phosphate. Calcium 
phosphate have been proved to be useful in not only 
in dentistry, but also bone grafts in orthopedics
6)
. 
There are many kinds of calcium phosphate 
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ABSTRACT
골 시멘트 자체 기능 외의 특성을 가질 수 있도록 하는 새로운 조성의 비정질 칼슘 포스페이트 분말을 개발하였다. 이 
분말로 만든 골 시멘트에서의 테트라사이클린 방출 거동은 두 가지 항생제 담지 방법으로 비교하였고, 이 전 논문에서 
이미 입증된 조성의 브러샤이트계 시멘트와도 비교하였다. 첫 번째 담지 방법은 시편의 마이크로 기공에 의해 발생하는 
삼투압 현상으로 항생제 약물에 시편을 담그어 담지시키는 방법이고, 다른 방법은 분말과 항생제를 용해시킨 액상을 섞
는 방법이다. 비정질 칼슘 포스페이트 분말은 유리 제조의 전형적인 방법인 용해 후 급냉시키는 방법을 이용하여 얻은 
비정질 칼슘 포스페이트 유리를 갈아서 얻었다. 시멘트 페이스트를 섞을 때 중합열이 없기 때문에, 우리는 테트라사이클
린의 변성없이 골 시멘트 시편을 만들 수 있었다. 골 시멘트로부터의 테트라사이클린 방출 시험은 6일 간 진행되었고, 
그 결과 첫 번째 항생제 담지 방법으로 만든 시편보다 두 번째 방법으로 만든 시편으로부터 테트라시이클린 방출이 더욱 
지속적으로 나타났다. 또한 항생제 담지에 따른 물리적 성질의 변화를 고려하여 압축강도 시험을 하였다. 그 결과 테트
라 사이클린을 담지한 시편과 그렇지 않은 시편과의 통계학적 유의차는 없는 것으로 나타났다. 이런 결과를 토대로 새로
운 조성의 비정질 칼슘 포스페이트 시멘트는 다른 재료의 골 이식재처럼 생물학적 인자 혹은 약물 전달 시스템에 있어서 
충분한 가능성이 있다고 판단된다.
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materials. Calcium orthophosphate cement do not 
require sintering to make a specific shape
7)
. 
Therefore, calcium phosphate cement can contain 
biological molecules and drugs which are not dam-
aged their effects due to the low temperature proc-
ess, and can release continuously
8,9)
. On the other 
hands, calcium phosphate glass has advantages 
which can control compositions to react on hard tis-
sue easily and to regenerate hard tissue due to its 
biodegradable characteristic
10)
. But synthesis tem-
perature of calcium phosphate glass is still too high 
to contain biological molecules and drugs.
Therefore, we investigated brand-new composition 
bone cement powder and aqueous solution system 
using the amorphous calcium phosphate (ACP) glass 
and basic solution. The advantages of this cement 
are that eliminating needless process like the second 
heat treatment one for hardening and loading the 
biological molecules and drugs efficiently. The pow-
der from ACP glass was synthesized like self-setting 
reaction cement with aqueous solution at body 
temperature. Due to the temperature of cementation, 
we could load tetracycline (TTC) on that ACP glass 
powder and basic solution. Therefore, we experimented 
on the release of TTC which is known to have diverse 
characteristics as well as antibacterial characteristics. 
TTC hastens the attachment of cells on surface of 
dentin and has inhibition efficacy on collagenase. 
When it is administered a dose topically, TTC also 
help new bone formation
11,12,13)
.
The aim of this study is that new composition 
ACP cement has potential for containing antibiotics 
without denaterization and controlling the behaviors 
of release, that is, release contents of the anti-
biotics per time could be controlled easily by clini-
cians or the other users. We chose TTC which is 
one of the antibiotics, for release, and ex-
perimented on release test with two drug loading 
methods. We also compared with previously studied 
brushite cements.
MATERIALS AND METHODS
1. Synthesis of Amorphous Calcium Phosphate 
Glass Powder
Glass batch in the system CaO-P2O5-MgO-ZnO- 
CaF2 was prepared with Ca/P ratio 0.6 using CaCO3 
(Samchun Pure Chemical Co., Ltd., Korea), H3PO4, 
MgO, ZnO (Duksan Pure Chemical CP., Ltd., Korea), 
CaF2 (Junsei Chemical Co., Ltd., Japan)  as raw 
materials and the molar ratio of CaO/CaF2 was fixed 
to 9. MgO and ZnO were added at 1mol%, re-
spectively
14,15)
. Mixed batches were dried at 100℃ 
and melted in a platinum crucible at 1250℃. It was 
subsequently quenched onto a graphite plate con-
ventionally at room temperature. The ACP glass was 
reduced powder using an alumina mortar and was 
attrition milled using two different sizes of zirconia 
balls. To confirm non-crystalline phase, X-ray dif-
fraction analysis was performed (D/MAX 2000, 
Rigaku, Japan). The powder distribution analysis 
was performed using a particle size analyzer (Saturn 
DigiSizer◯R5200, Micrometritics, USA).
2. Preparation of bone cement specimen and 
loading tetracycline
The ACP glass powder and 1.5 M NaOH solution 
were main materials for bone cement. And Na2CO3 
were added for forming micro-pores and improving 
strength after immersing in phosphate buffer saline 
(PBS pH 7.4, Gibco, Invitrogen, USA). The amount 
of Na2CO3 was 7.5 wt% of whole powder and the ra-
tio of powder / liquid was 4 g/ml.
1) Experimental group (EG) : The mixed powder 
was added to TTC solution at a time and mixed 
with spatula for 20 seconds. TTC solution is 
that TTC was dissolved in 1.5 M NaOH solution 
with using stirrer bar for 3 minutes. This 
mixed paste was poured into a cylindrical 
Teflon mold (6 mm D × 12 mm H)
16)
. The upper 
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side and bottom of the mold were covered with 
glass plates and were fixed with C-clamp. 
Then the mold was placed in a 37℃, 100% rel-
ative humidity box. The mold was removed af-
ter 2 hours and was placed in same condition 
as before again for 22 hours.
2) Control group (CG) : The mixed powder was 
added to the NaOH solution at a time and 
mixed with spatula for 30 seconds. After ce-
mentation of the paste, specimens were im-
mersed for 10 minutes, 30 minutes, and 60mi-
nutes (CG-I : difference caused by loading 
methods) in prepared TTC solution which was 
made of 1.5 M NaOH solution and TTC. 
Afterward process were same with EG. After 
immersing, the specimen was dried at 37℃ for 
a day. This group was prepared to compare 
release behaviors with EG. As control group II, 
III (CG-II, CG-III : difference caused by com-
ponents of cements) in TTC release test, two 
brushite cement formulations were pre-
pared
17,18)
. These two groups were prepared to 
compare release behaviors with EG-c. The 
components of cements and the contents of 
loaded TTC  are presented in Table 1.
3. Release Behavior of Tetracycline
The specimens of each group were immersed in 
PBS and stored in 37℃ chamber for 6 days with a 
change of the effluent after measurement absorb-
ance (1 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 
6 days). The volume of PBS was 3 mℓ for each 
specimen and they were completely surrounded by 
the solution. The absorbance measurement of efflu-
ent was performed at 362 nm using a UV/vis spec-
trometer (UVD-3200, Labomed, Inc., USA). Quantity 
of tetracycline was acquired through drawing the 
calibration curve.
4. Compressive strength
There was a compressive strength test to compare 
TTC loaded bone cements and unloaded bone cement. 
The specimens were cylindrical shape those were 
made in the same process as above. Some specimens 
were immersed in 37℃ PBS for 1 day. The volume of 
PBS was twice as much as that of specimens. The 
specimens were immediately measured by a universal 
testing machine (3366, Instron, USA). The cross- 
head speed was 1 mm/min and picked the maximum 
value of strength out
16)
. Results were compared us-
ing one-way ANOVA analysis variance followed by a 
Tukey post hoc test (SPSS, v12.0).
RESULTS
1. Properties of amorphous calcium phos-
phate glass powder
As a result of XRD analysis, there was none crys-
Table 1. The components of cements and the contents of loaded TTC on each groups per specimen are presented. The 
contents were calculated by bulk specimen reducing powder and dissolve in PBS. Then we acquired the amount of loaded 
TTC using absorbance of TTC from UV/vis spectrometer
Cement 
codes
Component Content of TTC (mg)
Powder phase Liquid phase P/L ratio (g/ml) a b c
EG 92.5 wt% ACP glass
7.5 wt% Na2Co3
1.5 M NaOH 4.0
412.5 825 1650
CG
I 764.5 974 959.5
II
a β-TCP
0.2 M H3PO4 






0.5 M sodium citrate 3.3
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talline peak. Therefore, we could conclude that the 
calcium phosphate glass powder had amorphous 
phase. The powder size was distributed at about 5 
μm and 1.5 μm broadly, due to the two different 
size of zirconia balls which used in attrition milling. 
Therefore, we could expect that the binary particle 




2. Release behavior of tetracycline
The release of TTC under two method conditions 
showed very different aspects (Fig. 1). In the CG-I, 
each and every dipping time conditions followed a 
first order kinetic with an initial burst release, 
where upto 30% of loaded TTC was released within 1 
day. The reason of an initial burst release was that 
the micro-pores of bone cement specimen were not 
consisted of open pores but most of those are closed 
pores. Therefore, it was difficult to absorb the tet-
racycline solution broadly. Therefore, most of TTC 
which was burst at the initial stage release was that 
absorbed only inside the surface nearby of the cy-
lindrical specimen. In contrast, the case of EG in-
dicated that the release of TTC from cylindrical 
specimens showed no initial burst of TTC and the 
slopes of EG were regular. These results proved that 
loaded TTC were spread broadly inside the bone ce-
        
Figure 1. The release behaviors of TTC from CG-I and EG. (a) CG-I showed initial burst release and after 1day, the release
rate of TTC was very slow. (b) EG showed no initial burst and constant release (n=3).
     
Figure 2. The release behaviors of TTC from EG-c, 
CG-II-a, b (n=3). The characteristics of each cement 
specimen (P/L ratio, component, etc.) let them be different.
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ments specimen. When the specimens were made, 
TTC was not powder, but was solute of NaOH 
solution. Therefore TTC could spread broadly into 
the specimen, and release rate was nearly constant. 
Fig. 2 showed the release behaviors of TTC from 
EG-c, CG-II-a, and CG-II-b. They had same con-
tents of TTC but cumulative rate were different. The 
reason of different cumulative rate is their P/L 
ratio. P/L ratio has an effect on setting time, po-
rosity, and strength
17)
. Actually, the result of com-
pressive strength test proved the theory.
3. Compressive strength
The results of compressive strength test were 
showed in Fig. 3. There were no statistical differ-
ence of compressive strength between TTC unloaded 
specimens and unloaded specimens, neither harden-
ing at 37℃ nor immersing in PBS at 37℃. There 
was no significant difference between TTC free 
specimens and EG (p<0.05). As shown Fig. 3, results 
of wet condition told us that the relationship be-
tween P/L ratio and strength. As P/L ratio in-
creased, strength increase, too.
DISCUSSION
Hard tissue of human body consists of various 
elements. Main element is that we called the hy-
droxyapatie (HA) which consists of calcium and 
phosphorus with their ratio is 1.67. ACP glass we 
are investigating is similar to ingredients of the HA 
and has many advantages. The way of synthesis of 
ACP glass is not complex as well as synthesis of HA. 
Therefore, we could approach easily to acquire the 
artificial bone through synthesizing ACP glass.
We investigated this ACP glass and the composi-
tion what we applied is suitable for applying 
self-hardening bone cement. Because, there was no 
heat of polymerization, we could conceive that bio-
logical molecules and drugs could be additives of our 
ACP bone cement easily. We experienced that the 
control of drug quantity is difficult to mix paste and 
physical characteristic could be weakened, if amount 
of drug is added on amorphous calcium phosphate 
powder. Therefore, we conceived that drug might be 
as well loaded by liquid phase as powder form. And 
this way has many advantages that when we mixed 
paste and the paste was hardened, the loaded drug 
could be dispersed broadly. Therefore, the drug could 
release constantly and continuously. The release test 
of TTC was fine we expected, because of broad dis-
persion of TTC inside specimen. But the CG-I was 
not. The reason was that micro-pores inside bone 
cement specimen were closed pores (not inter-con-
nective). Therefore, it is difficult to pass through 
and too low pressure to soak the drug solution.
Comparing the release behavior of TTC from ACP 
              
Figure 3. The results of compressive strength test (n=10). (a) is a graph of dry condition. The results of wet condition (b)
showed that each group has different characteristics. The results of CG-II-a, b were quoted from reference 17,18.
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bone cement under mixing powder and antibiotic 
solution system with simple dipping method showed 
that drug release behavior can be controlled by the 
former. The drug release result from this method 
showed no initial burst release behavior and no de-
naturalization of mechanical property (ACP bone ce-
ment specimen). Especially, there did not need to 
devise special and complex device for drug loading 
due to the ACP cement. And this showed us that the 
potential which is abilities to load biological mole-
cules and various drugs and for other bone grafts to 
release drugs efficiently through ACP coating. But 
one thing we mistook in this experiment is that mi-
cro-pores inside bone cement specimen were closed 
pores. Therefore, it was difficult to adapt capillary 
phenomenon as a control group. In following inves-
tigation, we should consider another method to load 
biological molecules and drugs for control group and 
another bone grafts. Furthermore, we should find 
out various factors which can affect when drugs are 
loaded on bone cement.
REFERENCES
 1. Li LC, Deng J, Stephens D (2002). Polyanhydride implant 
for antibiotic delivery--from the bench to the clinic. Adv 
Drug Deliv Rev 54(7):963-986.
 2. Schlapp M, Friess W (2003). Collagen/PLGA microparticle 
composites for local controlled delivery of gentamicin. J 
Pharm Sci 92(11):2145-2151.
 3. Wu P, Grainger DW (2006). Drug/device combinations for 
local drug therapies and infection prophylaxis. Biomaterials 
27(11):2450-2467.
 4. Bryskier A (2005). Antimicrobial agents : antibacterials and 
antifungals. Washington, D.C.: ASM Press; pp. 1426.
 5. Budavari S (2001). The Merck index : an encyclopedia of 
chemicals, drugs, and biologicals. 13th ed. N.J., U.S.A.: 
Merck & Co., Inc.; various pages.
 6. LeGeros RZ (1991). Calcium phosphates in oral biology 
and medicine. Basel, Switzerland. S. Karger AG; pp. 1-201.
 7. Dorozhkin SV (2008). Calcium orthophosphate cements for 
biomedical application. J Mater Sci Mater Med 43(9): 
3028-3057.
 8. Ginebra MP, Traykova T, Planell JA (2006). Calcium phos-
phate cements as bone drug delivery systems: a review. J 
Control Release 113(2):102-110.
 9. Ginebra MP, Traykova T, Planell JA (2006). Calcium phos-
phate cements: competitive drug carriers for the muscu-
loskeletal system? Biomaterials 27(10):2171-2177.
10. Lee YK, Song J, Lee SB, Kim KM, Choi SH, Kim CK, 
LeGeros RZ, Kim KN (2004). Proliferation, differentiation, 
and calcification of preosteoblast-like MC3T3-E1 cells cul-
tured onto noncrystalline calcium phosphate glass. J 
Biomed Mater Res A 69A(1):188-195.
11. Somerman MJ, Foster RA, Vorsteg GM, Progebin K, Wynn 
RL (1988). Effects of minocycline on fibroblast attachment 
and spreading. J Periodontal Res 23(2):154-159.
12. Golub LM, Ciancio S, Ramamamurthy NS, Leung M, 
McNamara TF (1990). Low-dose doxycycline therapy: ef-
fect on gingival and crevicular fluid collagenase activity in 
humans. J Periodontal Res 25(6):321-330.
13. Goodson J (2000). Antimicrobial strategies for treatment of 
periodontal disease. J Periodontol 5:142-168.
14. Legeros RZ, Lee YK (2004). Synthesis of amorphous cal-
cium phosphates for hard tissue repair using conventional 
melting technique. J Mater Sci Mater Med 39(16):5577-5579.
15. Lee BH KM, Choi SH, Lee YK (2008). Amorphous cal-
cium polyphosphate bone regenerative materials based on 
calcium phosphate glass. Key Engineering Materials 
396:209-212.
16. International Standards Organization. ISO 9917-1: 2007(E). 
Water-based cements - Part 1: Powder/liquid acid-base cements. 
Geneva:ISO, 2007.
17. Grover LM, Knowles JC, Fleming GJP, Barralet JE (2003). 
In vitro ageing of brushite calcium phosphate cement. 
Biomaterials 24(23):4133-4141.
18. Barralet JE, Grover LM, Gbureck U (2004). Ionic mod-
ification of calcium phosphate cement viscosity. Part II: hy-
podermic injection and strength improvement of brushite 
cement. Biomaterials 25(11):2197-2203.
19. Coble RL (1973). Effects of Particle-Size Distribution in 
Initial-Stage Sintering. J Am Ceram Soc 56(9):461-466.
20. Bittner B, Mader K, Kroll C, Borchert HH, Kissel T 
(1999). Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) 
microspheres prepared by a spray drying technique: influ-
ence of gamma-irradiation on radical formation and poly-
mer degradation. J Control Release 59(1):23-32.
